Evidence map›Paper›PMID 42801155›Full record

ArticleEndocrine oncology (Bristol, England)2026

Clinical application of digital pathology in small intestinal neuroendocrine tumours: proposal of a new G0 category.

Nathalie Guedj, Guillaume Cléry, Anaïs Chassac, Nathalie Colnot, Vinciane Rebours, Jérôme Cros, Louis de Mestier, Anne Couvelard, Matthieu Tihy

Abstract read
In one paragraph

Article in Endocrine oncology (Bristol, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nathalie GuedjUniversité Paris-Cité, Department of Pathology, ENETS Center of Excellence, Beaujon Hospital (APHP.Nord), Clichy, France.
Guillaume CléryUniversité Paris-Cité, Department of Pancreatology and Digestive Oncology, Beaujon Hospital (APHP.Nord), Clichy, France.
Anaïs ChassacUniversité Paris-Cité, Department of Pathology, Bichat Hospital (APHP.Nord), Paris, France.
Nathalie ColnotUniversité Paris-Cité, Department of Pathology, ENETS Center of Excellence, Beaujon Hospital (APHP.Nord), Clichy, France.
Vinciane ReboursUniversité Paris-Cité, Department of Pancreatology and Digestive Oncology, Beaujon Hospital (APHP.Nord), Clichy, France.
Jérôme CrosUniversité Paris-Cité, Department of Pathology, ENETS Center of Excellence, Beaujon Hospital (APHP.Nord), Clichy, France.ORCID https://orcid.org/0000-0002-4935-3865
Louis de MestierUniversité Paris-Cité, Department of Pancreatology and Digestive Oncology, Beaujon Hospital (APHP.Nord), Clichy, France.ORCID https://orcid.org/0000-0001-9715-9189
Anne CouvelardUniversité Paris-Cité, Department of Pathology, Bichat Hospital (APHP.Nord), Paris, France.
Matthieu TihyUniversité Paris-Cité, Department of Pathology, ENETS Center of Excellence, Beaujon Hospital (APHP.Nord), Clichy, France.ORCID https://orcid.org/0000-0002-9314-4657

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Small intestinal neuroendocrine tumours (siNETs) are usually indolent neoplasms, most of which are classified as grade 1 with very low proliferative activity. In practice, Ki-67 in G1 siNETs is often reported simply as '<3%', limiting prognostic discrimination. Digital pathology now enables reliable automated quantification of very low Ki-67 values. We investigated whether precise Ki-67 quantification could improve prognostic stratification in G1 siNETs. Methods: We retrospectively included 63 consecutive patients who underwent surgery for a G1 siNET at Beaujon Hospital between 2001 and 2017. Ki-67 was quantified on primary tumours (PTs) and, when available, lymph node and liver metastases, using QuPath automated image analysis. Ki-67 was assessed in the highest-proliferation hotspot (0.4 mm Results: Among 63 patients, 33 underwent curative-intent surgery (median age: 56 years; 69% male). Median tumour size was 20 mm. At surgery, 87% were node-positive and 67% had synchronous metastases. Median Ki-67 Conclusion: Precise digital Ki-67 quantification refines prognostic stratification in G1 siNETs. Tumours with Ki-67 <1% may represent a biologically distinct 'G0' subgroup associated with extremely low recurrence risk after curative surgery.

Indexed as

Ki-67MIBneuroendocrine tumourssiNETs

Identifiers

PMID42801155
PMCPMC13615843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.